Entry requirements: The programme in Master of Science in Pharmacy: at least 150 credits within the programme including passed courses in pharmacokinetics 7.5 credits, pharmacology and physiology. Furthermore, registration at all earlier courses within the pharmacy program is required The programme in Master of Science in Chemical Engineering: at least 150 credits within the programme is required, and courses corresponding to Pharmacokinetics 7.5 credits, Physiology 6 credits and Pharmacology 7.5 credits Master Programme in Biological drugs: admitted and complied prior courses within the program Master Programme in Drug Discovery and Development: admitted and complied prior courses within the program Master Programme in Pharmaceutical Modelling: admitted and complied prior courses within the program Acceptance to a single subject course requires a) basic qualification according to the higher education ordinance (150 credits), and b) knowledge corresponding to 60 credits within the subject Pharmacy, Pharmaceutical science, or Pharmaceutical bioscience, including Pharmacokinetics 7.5 credits, and c) knowledge corresponding to Physiology 6 credits and Pharmacology 7.5 credits
If you are not a citizen of a European Union (EU) or European Economic Area (EEA) country, or Switzerland, you are required to pay application or tuition fees. Formal exchange students will be exempted from tuition fees, as well as the application fee. Read more about fees.
Application fee: SEK 900
Tuition fee, first semester:
Tuition fee, total:
About the course
The course provides a detailed picture of how different biological medicines are distributed and eliminated and how different target structures and disease states can affect their dose-concentration-effect relationship. Through lectures and workshops, the course sheds light on how the relationships affect both drug development and use, in comparison with more traditional drugs.
The course focuses on protein medicines and antibodies, but also covers other types of biological medicines such as peptides, oligonucleotides, vaccines and cell therapies. We also discuss how knowledge about how the dose-response relationships of biological medicines in preclinical studies are used to define clinical study design.